Telesis Bio, Inc.
TBIO
$4.50
$0.153.45%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -26.32% | -16.64% | 53.00% | 12.07% | 207.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.32% | -16.64% | 53.00% | 12.07% | 207.63% |
| Cost of Revenue | -26.30% | -14.89% | 0.54% | -16.76% | 37.66% |
| Gross Profit | -26.33% | -18.09% | 109.92% | 62.83% | 630.84% |
| SG&A Expenses | -25.76% | -4.77% | -11.48% | 0.27% | 30.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.69% | -12.50% | -17.50% | -6.55% | 16.66% |
| Operating Income | 22.73% | 10.04% | 45.01% | 14.71% | 33.17% |
| Income Before Tax | -117.62% | 13.74% | 44.13% | 15.71% | 34.92% |
| Income Tax Expenses | -50.00% | 133.33% | -33.33% | -50.00% | 50.00% |
| Earnings from Continuing Operations | -117.50% | 13.67% | 44.12% | 15.73% | 34.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.50% | 13.67% | 44.12% | 15.73% | 34.90% |
| EBIT | 22.73% | 10.04% | 45.01% | 14.71% | 33.17% |
| EBITDA | 26.22% | 12.10% | 47.25% | 16.56% | 35.95% |
| EPS Basic | -121.26% | 10.35% | 43.73% | 16.67% | 35.44% |
| Normalized Basic EPS | 25.28% | 9.62% | 44.76% | 16.87% | 33.78% |
| EPS Diluted | -121.26% | 10.35% | 43.73% | 16.67% | 35.44% |
| Normalized Diluted EPS | 25.28% | 9.62% | 44.76% | 16.87% | 33.78% |
| Average Basic Shares Outstanding | 1.51% | 1.45% | 1.15% | 1.13% | 0.86% |
| Average Diluted Shares Outstanding | 1.51% | 1.45% | 1.15% | 1.13% | 0.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
